Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jan 17;62(2):373–381. doi: 10.2337/db12-0202

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 3. — Inhibition of DPP-4 augments GLP-1 action, resulting in decreased postprandial lipemia in GLP-1/GLP-2–coinfused hamsters. A: Chow-fed hamsters received treatment with the DPP-4 inhibitor sitagliptin (intraperitoneal) 30 min prior to experiments, and then received an oral fat load followed by a 30-min intravenous infusion of either VEH, GLP-1, GLP-2, or GLP-1 and GLP-2; poloxamer was administered 20 min post–fat load (intraperitoneal). Blood was collected at 30, 60, 90, and 120 min to assess lipemia. B: A representative blot of TRL-apoB48 is shown along with a graph showing quantification of apoB48. Plasma (C) and TRL-TG (D) levels and plasma (E) and TRL-cholesterol (F) levels were quantified and represented in graphs (n = 4–5). Each graph represents the mean ± SEM at each time point for the given parameter. Calculated slopes are shown within each graph (n = 4–5; *P < 0.05 vs. GLP-1, #P < 0.05 vs. GLP-2, ^P < 0.05 vs. GLP-1 + GLP-2).